Ra Capital Management, L.P. Sells 530,610 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Key Points

• Ra Capital Management, L.P. sold 530,610 Vor Biopharma shares on April 13 at an average price of $16.15, a move that cut its stake by 13.48% to 3,404,998 shares valued at about $55.0 million.
• The firm executed multiple early‑April trades totaling roughly 2.21 million shares for about $36.6 million, signaling significant insider‑affiliated liquidation over several days.
• Vor’s stock traded near $15.60 with heavy institutional ownership (97.29%) and a consensus analyst price target of $50.56 (average rating: Moderate Buy), despite a 12‑month range of $2.62–$65.80.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 530,610 shares of the company's stock in a transaction on Monday, April 13th. The shares were sold at an average price of $16.15, for a total value of $8,569,351.50. Following the completion of the transaction, the director owned 3,404,998 shares of the company's stock, valued at $54,990,717.70. This trade represents a 13.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The shares were sold at an average price of $16.01, for a total value of $858,840.44.
• On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total value of $2,455,147.95.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total value of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total value of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00.

Vor Biopharma Stock Performance

NASDAQ:VOR traded down $0.27 during trading on Wednesday, reaching $15.60. The company's stock had a trading volume of 880,470 shares, compared to its average volume of 1,019,622. The firm has a market cap of $762.06 million, a price-to-earnings ratio of -0.04 and a beta of 1.92. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80. The firm has a 50 day moving average of $14.60 and a 200-day moving average of $16.68.

Institutional Trading of Vor Biopharma

A number of institutional investors have recently added to or reduced their stakes in VOR. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $229,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $134,000. Tudor Investment Corp ET AL purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $2,193,000. Sphera Funds Management LTD. purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $5,368,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $350,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

Analysts Set New Price Targets

VOR has been the topic of several recent research reports. HC Wainwright dropped their price objective on shares of Vor Biopharma from $32.00 to $31.00 and set a "buy" rating on the stock in a report on Wednesday. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a report on Thursday, March 19th. They set an "overweight" rating and a $30.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, January 21st. Jefferies Financial Group initiated coverage on shares of Vor Biopharma in a report on Monday, March 30th. They set a "buy" rating and a $50.00 price objective on the stock. Finally, TD Cowen initiated coverage on shares of Vor Biopharma in a report on Wednesday, December 17th. They set a "buy" rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.56.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.